New data presented at International Conference on Alzheimer's and
VANCOUVER, March 12, 2013 /PRNewswire/ - Anavex Life Sciences Corp. ("Anavex")
(OTCQB: AVXL) today announced more promising new data for ANAVEX 2-73,
the company's lead drug candidate for Alzheimer's disease.
In a scientific study conducted in France at the University of
Montpellier and INSERM, ANAVEX 2-73 demonstrated disease-modifying
effects, including the ability to repair normal mitochondrial
functionality in the hippocampus, the part of the brain involved with
learning, memory and emotions. Mitochondrial dysfunction has been
consistently reported as an early cause of Alzheimer's disease. It
appears before amyloid-beta plaques can start to accumulate and memory
loss begins in Alzheimer's patients and transgenic mice. In the same
study, ANAVEX 2-73 blocked apoptosis (cell death) and oxidative stress,
which is believed to prevent the onset of Alzheimer's disease.
"ANAVEX 2-73 appears to be a valuable drug for protection against
mitochondrial damages relative to Alzheimer's disease physiopathology,"
said Tangui Maurice, PhD, CNRS Research Director, Head of Team 2
'Endogenous Neuroprotection in Neurodegenerative Diseases', at the
University of Montpellier and INSERM. "The unique target combination
of the drug is responsible for its activity on mitochondrial
dysfunction which is likely the triggering event of the pathology."
The new study data was revealed in a presentation at the international
conference on Alzheimer's and Parkinson's Diseases in Florence, Italy.
Now in its 11th year, the conference attracts leading international medical and
scientific experts from around the world. The presentation is titled,
"Mitochondrial protection in mouse hippocampus against Aß25-35 toxicity
is induced by the
novel tetrahydrofuran derivative ANAVEX2-73, a mixed 1 receptor and
The study was jointly conducted by Valentine Lahmy, PharmD, Romain Long,
PhD, Didier Morin, PhD, team leader at INSERM, Institut Henri Modor,
Créteil, Vanessa Villard, PhD, CEO of Amylgen, Alexandre Vamvakides,
PhD, Scientific Founder of Anavex, and Tangui Maurice, PhD. Full
details of the study are described on Anavex's website at http://www.anavex.com/files/1303_ADPD_Valentine.pdf.
About Anavex Life Sciences Corp.
Anavex Life Sciences Corp. (www.anavex.com) is a pharmaceutical company engaged in the development of novel drug
candidates. ANAVEX 2-73, a drug candidate developed to treat
Alzheimer's disease through disease modification, has undergone an
initial Phase 1 human clinical trial and was well tolerated in doses up
to 55mg. Sponsored pre-clinical studies indicate that ANAVEX 2-73
demonstrates anti-amnesic and neuroprotective properties. Anavex is a
publicly traded corporation quoted as AVXL.
Statements in this press release that are not strictly historical in
nature are forward-looking statements. These statements are only
predictions based on current information and expectations and involve a
number of risks and uncertainties. Actual events or results may differ
materially from those projected in any of such statements due to
various factors, including the risks and uncertainties inherent in drug
discovery and development, which include, without limitation, the
potential failure of development candidates to advance through
preclinical studies or demonstrate safety and efficacy in clinical
testing and the ability to pass clinical trials so as to move on to the
next phase, our ability to finance development or satisfy the rigorous
regulatory requirements for new drugs, our ability to attract and
retain quality personnel, and that despite positive results, our
competitors may offer better or cheaper alternatives. Readers are
cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date hereof. All
forward-looking statements are qualified in their entirety by this
cautionary statement and Anavex Life Sciences Corp. undertakes no
obligation to revise or update this press release to reflect events or
circumstances after the date hereof.
Anavex Life Sciences Corp.
Research & Business Development
Shareholder & Media Relations
Outside North America: +1 (416) 489-0092
SOURCE Anavex Life Sciences Corp.